

Milford Global Opportunities Fund - R Class

July 2022

Portfolio Managers



Alexander Whight
Portfolio Manager



Stephen Johnston
Co-Portfolio Manager


The Fund returned 6.1% in July, with the benchmark up 6.4%.

In July, positive contributors included HCA Healthcare (+26.4%), after it reported better than feared profits in a challenging environment for hospital operators. We expect continued positive progress as contract labour usage normalises lower and inflationary trends are passed on to payers in 2023 and 2024. Analog Devices increased 17.7% as the market began to look through a potential downturn in semiconductor sales. Accounting software firm, Intuit, rose 18.5%, as the market reassessed its willingness to pay for long term growth stocks.

Detractors included pharmaceutical company Bristol-Myers Squibb (-4.2%), which underperformed in the rotation back towards higher growth stocks and amidst renewed discussions of US drug price reform. We took the opportunity to add to our position as we expect a positive revaluation of the shares as it enhances a maturing in-market drug portfolio with its diverse drug development pipeline. TransUnion (-1.0%) reported slower than expected sales growth and lowered 2022 guidance in a weaker economic environment and mixed progress with recent acquisitions.

Volatile equity markets may persist with moderating earnings growth, inflation, central bank tightening and the ongoing pandemic. Uncertainty creates opportunity, and we continue to focus on attractively valued, quality companies with idiosyncratic drivers of investment returns.

Investment Performance to July 2022*



* Cumulative performance since inception, after all fees and expenses, and assumes reinvestment of distributions.

Key Fund Facts

Objective	To out-perform the MSCI World Net TR Index (AUD) over a rolling 8-year period (net of fees)
Description	Exposure to primarily global equity securities that are attractively valued
Benchmark	MSCI World Net TR Index (AUD)
APIR	ETL4466AU
Redemption Price as at 31 Jul	\$0.9761
NAV as at 31 Jul	\$50.4 Million
Inception Date	February 2022
Minimum Investment	\$1,000
Recommended Investment Timeframe	8 years +
Buy-sell Spread	+/-0.20%
Entry/Exit Fee	Nil
Management Fee	1.15%
Performance Fee	15% p.a. of returns above the benchmark subject to achieving the high watermark.
Fund Pricing	Daily
Distribution Frequency	Biannual

Investment Performance to July 2022

	1 Month	6 Months	1 year	3 years (p.a.)	5 years (p.a.)	Since Inception
Milford Global Opportunities Fund	6.13%	-	-	-	-	-1.37%
Benchmark	6.37%	-	-	-	-	-3.80%
Over/Underperformance	-0.24%	-	-	-	-	2.43%

Past performance is not a reliable indicator of future performance.

Top Security Holdings


Holdings	% of Fund
FIS	5.88%
Boston Scientific	5.62%
Bristol-Myers Squibb	5.28%
Intuit	4.59%
HCA Holdings	4.54%
Wyndham Hotels	4.14%
Ametek	4.09%
Electronic Arts	4.01%
Analog Devices	3.80%
Elevance Health	3.80%

Current Asset Allocation

	Actual	Neutral	Maximum Range
International Equities	96.81%	97.0%	80-100%
Australian Equities	0%	0%	0-10%
Cash and Other #	3.19%	3.0%	0-20%

Cash and Other reported above is adjusted to reflect the Fund's notional positions.

Sector Allocation



Fund Changes

There have been no material changes to the Fund's risk profile or strategy since the last monthly report. There have been no changes to the key service providers or individuals playing a key role in investment since the last monthly report.

Disclaimer: Equity Trustees Limited ("Equity Trustees") (ABN 46 004 031 298), AFSL 240975, is the responsible Entity for the Milford Global Opportunities Fund. Equity Trustees is a subsidiary of EQT Holdings Limited (ABN 22 607 797 615), a publicly listed company on the Australian Securities Exchange (ASX: EQT). This Monthly Fact Sheet has been prepared by Milford Australia Pty Ltd. as the Investment Manager, to provide you with general information only. In preparing this Monthly Fact Sheet, we did not take into account the investment objectives, financial situation or particular needs of any particular person. It is not intended to take the place of professional advice and you should not take action on specific issues in reliance on this information. Neither Milford Australia Pty Ltd., Equity Trustees nor any of their related parties, employees or directors, provide any warranty of accuracy or reliability in relation to such information or accepts any liability to any person who relies on it. Past performance is not a reliable indicator of future performance. You should obtain a copy of the Product Disclosure Statement before making a decision about whether to invest in this product.

Milford Global Opportunities Fund(AU)'s Target Market Determination is available at <https://milfordasset.com.au/forms-documents.au>. The Target Market Determination is a document describing who this financial product is likely to be appropriate for (i.e. the target market), and any conditions around how the product can be distributed to investors. It also describes the events or circumstances where the Target Market Determination for this financial product may need to be reviewed